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Introduction
There are a number of available disease-modifying
therapies for Multiple Sclerosis (MS). Prevalence of
migraine is higher in SM patients than in the general
population, so possible effects of these preventive treat-
ments on migraine should be monitored. A review of
the literature on the subject is presented.
Methods
PubMed, Ovid and Google Scholar searches were con-
ducted looking for Migraine combined with Beta-Inter-
feron (bIFN), Glatiramer Acetate (GA), Natalizumab,
Fingolimod, Laquinimod, Teriflunomide, Azathioprine,
Methotrexate, Mitoxantrone and Ciclofosfamide.
Results
Use of bIFN-1a was related to worsening of previously
diagnosed migraine (37,5-41%, p<0.05) and to high per-
centage of de novo headache presentation (41-44%,
p=0.05, ¼ of which with migraine features).
GA was associated with only 11% of worsening of
migraine, and a direct comparison with bIFN showed
the latter as much more migraine-inducing.
Effects of Natalizumab on migraine were evaluated in
a small sample, but a significant reduction in migraine
frequency and MIDAS scores was detected.
Only spurious cases of worsening of migraine were
reported with use of Fingolimod.
Conclusions
Of all disease-modifying therapies used in MS, bIFN is the
only one which showed a clear association with worsening
of previous migraine. Interpretation of data is difficult on
increased incidence of migraine after starting a disease-
modifying treatment, due to uneasy distinction between
facilitation of a true migraine and secondary headache,
attributable to medications.
Migraine should always be carefully assessed in patients
affected by MS, in particular if treated with disease-modi-
fying medications, to evaluate eventual modification of
migraine itself.
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